Navigation Links
Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Date:11/29/2007

Management and Third-Party Investigators to Conduct Conference Call on December 10, 2007 to Discuss SNS-595 Clinical Trial Results and SNS-032

Non-clinical Data

SOUTH SAN FRANCISCO, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that it will present data on the company's two lead product candidates, SNS-595 and SNS-032, at the upcoming 49th Annual Meeting of the American Society of Hematology (ASH). This year's conference will be held December 8-11, 2007 at the Georgia World Congress Center in Atlanta, Georgia. On December 10, 2007, Sunesis management will host a conference call for investors to discuss the data being presented.

Jeffrey Lancet, M.D., of the H. Lee Moffitt Cancer Center & Research Institute will present results from Sunesis' Phase 1 clinical trial of SNS-595, a replication-dependent DNA damaging agent, as part of the oral session "Acute Myeloid Leukemias: Therapy, excluding Transplantation-Novel Therapies." The presentation, titled "SNS-595 Demonstrates Clinical Responses in a Phase 1 Study in Acute Leukemia," (Abstract no. 442), will be conducted in Room A411-A412 at 2:15 p.m. Eastern Time on Monday, December 10, 2007.

In addition, the company will present non-clinical data on SNS-032, a cyclin-dependent kinase (CDK) inhibitor, during poster session "CLL: Salvage Therapies and New Agents." The poster, "Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol" (Abstract no. 3112) will be presented in Hall B4 of the Georgia World Con
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
(Date:7/13/2014)... Epidemiologists forecast an increase in the diagnosed ... diagnosed incident cases in 2013 to 11,568 diagnosed incident ... of 4.35%, during the forecast period. In 2023, the ... cases of aGVHD in the 6MM, with 4,989 diagnosed ... of diagnosed incident cases of aGVHD, with 704 diagnosed ...
(Date:7/13/2014)... 2014 A decreased ability to identify odors ... Alzheimer,s disease, while examinations of the eye could ... with Alzheimer,s, in the brain, according to the ... the Alzheimer,s Association International Conference 2014 (AAIC 2014) ... the decreased ability to identify odors was significantly ...
(Date:7/13/2014)... Wright & Schulte LLC has learned that ... July of 2015, in U.S. District Court, District of ... discovery process in the South Carolina federal court ... the multidistrict litigation (MDL). The complaints pending in the ... allege that they took the statin medication to lower ...
(Date:7/13/2014)... Celebrity fitness trainer and former World Super ... with Aqua Health Labs for their flagship product PhytOriginal, ... The collaboration was recently announced live on ESPN Radio. ... actor, model, and a two time World Super Middleweight ... has prepared stars including Demi Moore, Hilary Swank and ...
(Date:7/13/2014)... Palatine, Illinois (PRWEB) July 13, 2014 Hope ... facilitating a monthly grief support group at the Tamarack Senior ... will be held at 10:30 A.M. on the 3rd Wednesdays ... July 16th, 2014 at the Tamarack Community located at 55 ... to all bereaved individuals and there is no cost for ...
Breaking Medicine News(10 mins):Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... known that HIV patients are at an increased risk of ... shows // aggressive antiretroviral therapy may help lower that risk. ... therapy was associated with a lower incidence of Kaposi sarcoma ... more than 7,300 patients infected with HIV and the data ...
... In a study published in Diabetes Care, March 2005, scientists ... ,Insulin sensitivity is the measure for the risk ... then he has a lower risk of heart problems. ... insulin to control blood sugar. As this happens the body ...
... and heart attack can be reduced for heart patients undergoing ... of an anti-clotting drug before the procedure is the answer.// ... catheter is threaded into an artery. The balloon is inflated ... A small synthetic tube - stent is used to hold ...
... is known to help in controlling obesity. A new study ... Obesity (2005) says that dietary calcium present in the yogurt ... in lipid utilization and decrease in lipogenesis. ... one group was put on balanced deficit diets and the ...
... standard treatment with levodopa can reduce the amount of ... fluctuations they experience during the day . ,For ... drug entacapone, which must be taken with every levodopa ... of the additional drugs were effective in reducing the ...
... being hailed by researchers for its ability to target cancer ... called ON01910 works by interfering with a molecule known as ... multiply. This molecule is found in higher numbers in cancerous ... have especially high amounts. ,The drug was tested ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: